Published in Cell Host Microbe on October 16, 2013
MicroRNAs regulate the immunometabolic response to viral infection in the liver. Nat Chem Biol (2015) 1.39
Identification of an endocytic signal essential for the antiviral action of IFITM3. Cell Microbiol (2014) 1.23
Interferon-stimulated genes: roles in viral pathogenesis. Curr Opin Virol (2014) 1.22
Innate immunity to adenovirus. Hum Gene Ther (2014) 1.15
RNA virus replication depends on enrichment of phosphatidylethanolamine at replication sites in subcellular membranes. Proc Natl Acad Sci U S A (2015) 1.09
Regulation of the trafficking and antiviral activity of IFITM3 by post-translational modifications. Future Microbiol (2014) 0.83
Broad-spectrum antivirals against viral fusion. Nat Rev Microbiol (2015) 0.82
Lipid interactions during virus entry and infection. Cell Microbiol (2014) 0.78
An Interferon Regulated MicroRNA Provides Broad Cell-Intrinsic Antiviral Immunity through Multihit Host-Directed Targeting of the Sterol Pathway. PLoS Biol (2016) 0.77
Adenovirus modulates Toll-like receptor 4 signaling by reprogramming ORP1L-VAP protein contacts for cholesterol transport from endosomes to the endoplasmic reticulum. J Virol (2017) 0.75
New targets for controlling Ebola virus disease. Natl Sci Rev (2015) 0.75
Antiviral actions of interferons. Clin Microbiol Rev (2001) 13.06
A diverse range of gene products are effectors of the type I interferon antiviral response. Nature (2011) 12.86
Interferon-inducible antiviral effectors. Nat Rev Immunol (2008) 9.68
The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell (2009) 7.88
IFITM3 restricts the morbidity and mortality associated with influenza. Nature (2012) 4.66
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med (2012) 3.89
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog (2011) 3.26
The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell (2013) 3.19
The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol (2012) 3.17
IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog (2011) 2.99
The IFITM proteins inhibit HIV-1 infection. J Virol (2010) 2.80
A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A (2010) 2.41
Systematic identification of type I and type II interferon-induced antiviral factors. Proc Natl Acad Sci U S A (2012) 2.18
25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production. Proc Natl Acad Sci U S A (2009) 2.14
Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity (2012) 2.13
Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog (2012) 1.97
The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. Immunity (2012) 1.96
IFITM proteins restrict viral membrane hemifusion. PLoS Pathog (2013) 1.86
The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe (2013) 1.86
Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation. Cell (2013) 1.69
S-palmitoylation and ubiquitination differentially regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated resistance to influenza virus. J Biol Chem (2012) 1.67
Lysobisphosphatidic acid controls endosomal cholesterol levels. J Biol Chem (2008) 1.62
Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons. J Leukoc Biol (2010) 1.61
Increased expression of LDL receptor-related protein 1 during human cytomegalovirus infection reduces virion cholesterol and infectivity. Cell Host Microbe (2012) 1.59
Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential. Proc Natl Acad Sci U S A (2011) 1.57
Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis. PLoS Biol (2011) 1.56
The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol (2013) 1.54
Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology (2012) 1.49
A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus. J Hepatol (2011) 1.41
IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology (2012) 1.36
Induction of fatty acid synthesis is a key requirement for phagocytic differentiation of human monocytes. Proc Natl Acad Sci U S A (2010) 1.35
Lipids as modulators of membrane fusion mediated by viral fusion proteins. Eur Biophys J (2007) 1.29
Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc Natl Acad Sci U S A (2010) 1.25
Multifaceted roles for lipids in viral infection. Trends Microbiol (2011) 1.22
Cell entry of enveloped viruses. Curr Opin Virol (2011) 1.18
Multiple interferon stimulated genes synergize with the zinc finger antiviral protein to mediate anti-alphavirus activity. PLoS One (2012) 1.16
Viperin: a multifunctional, interferon-inducible protein that regulates virus replication. Cell Host Microbe (2011) 1.14
HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study. PLoS One (2008) 1.14
AMP-activated kinase restricts Rift Valley fever virus infection by inhibiting fatty acid synthesis. PLoS Pathog (2012) 1.14
The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected "true" long-term nonprogressors. Blood (2003) 1.09
A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication. Gastroenterology (2013) 1.06
A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog (2013) 1.05
Lipids at the interface of virus-host interactions. Curr Opin Microbiol (2012) 1.03
Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One (2011) 0.93
Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs). Clin Res Hepatol Gastroenterol (2012) 0.89
Transcriptional profiling of the effects of 25-hydroxycholesterol on human hepatocyte metabolism and the antiviral state it conveys against the hepatitis C virus. BMC Chem Biol (2009) 0.88
DNA sensing unchained. Cell Res (2013) 0.85
Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antiviral Res (2012) 0.85
Statins and influenza: can we move forward? J Infect Dis (2011) 0.81
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc Natl Acad Sci U S A (2009) 3.49
Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc Natl Acad Sci U S A (2010) 2.97
Allele-specific targeting of microRNAs to HLA-G and risk of asthma. Am J Hum Genet (2007) 2.58
Dengue virus-induced autophagy regulates lipid metabolism. Cell Host Microbe (2010) 2.49
Functions of autophagy in normal and diseased liver. Autophagy (2013) 1.81
RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog (2009) 1.65
Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication. J Virol (2011) 1.58
Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog (2012) 1.41
Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest (2017) 1.39
Multifaceted roles for lipids in viral infection. Trends Microbiol (2011) 1.22
Western Zika Virus in Human Fetal Neural Progenitors Persists Long Term with Partial Cytopathic and Limited Immunogenic Effects. Cell Rep (2016) 1.16
Dengue virus and autophagy. Viruses (2011) 1.10
Lipids at the interface of virus-host interactions. Curr Opin Microbiol (2012) 1.03
A physical interaction network of dengue virus and human proteins. Mol Cell Proteomics (2011) 1.03
Manipulation or capitulation: virus interactions with autophagy. Microbes Infect (2011) 1.02
Hepatitis C virus-host interactions, replication, and viral assembly. Curr Opin Virol (2012) 0.97
Potential roles for cellular cofactors in hepatitis C virus replication complex formation. Commun Integr Biol (2009) 0.92
Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol (N Y) (2007) 0.89
EWSR1 binds the hepatitis C virus cis-acting replication element and is required for efficient viral replication. J Virol (2013) 0.86
Identification and comparative analysis of hepatitis C virus-host cell protein interactions. Mol Biosyst (2013) 0.83
Possibilities for RNA interference in developing hepatitis C virus therapeutics. Viruses (2010) 0.77
A summary of the 18th International Symposium on Hepatitis C Virus and Related Viruses. Gastroenterology (2012) 0.76
A Sense of Self: RIG-I's Tolerance to Host RNA. Immunity (2015) 0.75
A method of accelerating transport simulation when groundwater pumping is simulated. Ground Water (2011) 0.75